BCL2L1 and neoplasm: It was reported that tumor cells acquire TRAIL resistance by the upregulation of XIAP, c-FLIP, Bcl2, and Bcl-xL as antiapoptotic proteins [19,20], and activation of phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and NF-κB as proliferation activators [21,22].